Positive results for mirikizumab for ulcerative colitis in 12 week phase 3 induction study

This IL-23 inhibitor induced higher rates of clinical remission vs placebo in the LUCENT-1 study. It also achieved superiority to placebo for clinical response, endoscopic remission and symptomatic remission. It is now being investigated in the LUCENT-2 maintenance study

Biospace Inc.